Progenics Pharmaceuticals Inc. (PGNX) News
Filter PGNX News Items
PGNX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PGNX News From Around the Web
Below are the latest news stories about Progenics Pharmaceuticals Inc that investors may wish to consider to help them evaluate PGNX as an investment opportunity.
Lantheus Completes Merger with ProgenicsLantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it has completed its previously announced merger with Progenics Pharmaceuticals, Inc. ("Progenics") (Nasdaq: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer. The merger agreement was first announced on October 2, 2019. |
Independent Bank Group Set to Join S&P SmallCap 600Independent Bank Group Inc. (NASD: IBTX) will replace Progenics Pharmaceuticals Inc. (NASD: PGNX) in the S&P; SmallCap 600 effective prior to the opening of trading on Monday, June 22. S&P; Small-Cap 600 constituent Lantheus Holdings Inc. (NASD: LNTH) is acquiring Progenics Pharmaceuticals in a deal expected to be completed on or about June 19 pending final conditions. Post-acquisition, Lantheus Holdings will remain in S&P; SmallCap 600. |
Progenics Stockholders Approve Merger with LantheusNEW YORK, June 16, 2020 -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to. |
SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ: PGNX) in connection with the proposed acquisition of the company by Lantheus Holdings, Inc. ("LNTH") (NASDAQ: LNTH). Under the terms of the acquisition agreement, PGNX shareholders will receive 0.31 shares of LNTH for each PGNX share they own, representing implied per-share merger consideration of only $3.96 based on LNTH's May 26, 2020 closing price of $12.77. |
Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific ProgramProgenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that the results from the Phase 3 CONDOR trial evaluating the diagnostic performance and clinical impact of PyLTM (18F-DCFPyL) in men with biochemical recurrence of prostate cancer will be presented in an oral session at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. PyL is the Company’s PSMA-targeted small molecule positron emission tomography (PET) imaging agent designed to visualize prostate cancer. |
Progenics Class Action: Halper Sadeh LLP Announces Filing Of Shareholder Class Action Lawsuit Against Progenics Pharmaceuticals, Inc.; Investors Are Encouraged To Contact The FirmHalper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) in connection with the proposed merger between Progenics and Lantheus Holdings, Inc. The lawsuit seeks damages and/or equitable relief on behalf of Progenics shareholders under the federal securities laws. |
Edited Transcript of PGNX earnings conference call or presentation 7-May-20 12:30pm GMTQ1 2020 Progenics Pharmaceuticals Inc Earnings Call |
Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business UpdatePending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics and… |
Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Progenics Pharmaceuticals, Inc. (PGNX)Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Southern District of New York, Case No. 1:20-cv-02847 on behalf of shareholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ:PGNX) who have been harmed by Progenics' and its board of directors' (the "Board") alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the proposed merger of the Company with Lantheus Holdings, Inc. (the "Proposed Transaction"). |
Progenics Pharmaceuticals Sets First Quarter 2020 Financial Results and Business Update Call for May 7Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call and webcast to review first quarter ended March 31, 2020 financial results on Thursday, May 7, 2020, at 8:30 a.m. ET. A live webcast will be available in the Media Center of the Progenics website, www.progenics.com, and a replay will be available there for two weeks. Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including: therapeutic agents designed to treat cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane antigen (“PSMA”) targeted imagi... |